Your browser doesn't support javascript.
loading
Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis.
Gertz, Morie; Abonour, Rafat; Gibbs, Sarah N; Finkel, Muriel; Landau, Heather; Lentzsch, Suzanne; Lin, Grace; Mahindra, Anuj; Quock, Tiffany; Rosenbaum, Cara; Rosenzweig, Michael; Sidana, Surbhi; Tuchman, Sascha A; Witteles, Ronald; Yermilov, Irina; Broder, Michael S.
Afiliación
  • Gertz M; Department of Medicine, Mayo Clinic, Rochester, MN, USA.
  • Abonour R; Department of Medicine, Indiana University School of Medicine; Director, Multiple Myeloma, Waldenstrom's Disease and Amyloidosis Program, Indianapolis, IN, USA.
  • Gibbs SN; PHAR (Partnership for Health Analytic Research), Beverly Hills, CA, USA.
  • Finkel M; Amyloidosis Support Groups Inc, Wood Dale, IL, USA.
  • Landau H; Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
  • Lentzsch S; Multiple Myeloma and Amyloidosis Program, Columbia University Medical Center, New York, NY, USA.
  • Lin G; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
  • Mahindra A; Malignant Hematology, Scripps Clinic MD Anderson Cancer Center, La Jolla, CA, USA.
  • Quock T; Health Economics and Outcomes Research, Prothena Biosciences Ltd., South San Francisco, CA, USA.
  • Rosenbaum C; Department of Medicine, Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA.
  • Rosenzweig M; Division of Multiple Myeloma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
  • Sidana S; Division of Cardiovascular Medicine, Stanford School of Medicine, Palo Alto, CA, USA.
  • Tuchman SA; Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
  • Witteles R; Division of Cardiovascular Medicine, Stanford School of Medicine, Palo Alto, CA, USA.
  • Yermilov I; PHAR (Partnership for Health Analytic Research), Beverly Hills, CA, USA.
  • Broder MS; PHAR (Partnership for Health Analytic Research), Beverly Hills, CA, USA.
Clinicoecon Outcomes Res ; 15: 673-680, 2023.
Article en En | MEDLINE | ID: mdl-37719133
ABSTRACT

Purpose:

Patients with diagnosed with systemic light chain (AL) amyloidosis at advanced Mayo stages have greater morbidity and mortality than those diagnosed at non-advanced stages. Estimating service use by severity is difficult because Mayo stage is not available in many secondary databases. We used an expert panel to estimate healthcare utilization among advanced and non-advanced AL amyloidosis patients. Patients and

Methods:

Using the RAND/UCLA modified Delphi method, expert panelists completed 180 healthcare utilization estimates, consisting of inpatient and outpatient visits, testing, chemotherapy, and procedures by disease severity and organ involvement during two treatment phases (the 1 year after starting first line [1L] therapy and 1 year following treatment [post-1L]). Estimates were also provided for post-1L by hematologic treatment response (complete or very good partial response [CR/VGPR], partial, no response or relapse [PR/NR/R]). Areas of disagreement were discussed during a meeting, after which ratings were completed a second time.

Results:

During 1L therapy, 55% of advanced patients had ≥1 hospitalization and 38% had ≥2 admissions. Rates of hematopoietic stem cell transplant (HSCT) in advanced patients were 5%, while pacemaker or implantable cardioverter defibrillator (ICD) placement were 15%. During post-1L therapy, rates of hospitalization in advanced patients remained high (≥1 hospitalization 20-43%, ≥2 hospitalizations 10-20%), and up to 10% of advanced patients had a HSCT. Ten percent of these patients underwent pacemaker/ICD placement.

Conclusion:

Experts estimated advanced patients, who would not be good candidates for HSCT, would have high rates of hospitalization (traditionally the most expensive type of healthcare utilization) and other health service use. The development of new treatment options that can facilitate organ recovery and improve function may lead to decreased utilization.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Clinicoecon Outcomes Res Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Clinicoecon Outcomes Res Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos